Skip to main content
ALC logo

Alcon Inc. (ALC) Stock: Price, Forecast & Analyst Target

Alcon Inc. (ALC) — MoonshotScore 80/100 (Exceptional band), calculated Nov 18, 2026. Price $74.52 (-0.98%), as of the Nov 19, 2026 trading session; market cap $35.8B.

Educational signal · not a buy or sell recommendation · How to read this

$74.52 −$0.74 (-0.98%) Market Cap $35.8B

Alcon Inc. · ALC · NYSE · Healthcare · Medical - Specialties

Research dated 2026-09-12: Alcon sells eye-surgery systems, implantable lenses, procedure consumables, contact lenses and ocular-health products under the ALC ticker. Equipment comparisons are becoming harder just as newer products are expected to contribute more, making sustained sales momentum and recovery in reported operating profit the defining test.

Price as of Nov 19, 2026

Key Statistics

80 of 100

MoonshotScore v2 · Alcon (ALC)

Exceptional
Business Quality Solid (76)
Financial Safety Sound (74)
Valuation Fair (64)
Growth Durability Growing (74)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.

  • quarterly revenue $2.82B (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 6 of the last 8 reports
  • Altman Z 2.83 · Piotroski F 8

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ALC (52 recorded, newest six shown)
RecordedScoreBand
80Exceptional
81Exceptional
81Exceptional
81Exceptional
80Strong
80Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$74.52
Change on the day-0.98%
52-week range$61.84–$87.64
Market capitalisation$35.8B—
Price / earnings (trailing)54.49
Shares traded on the day3.70M
Beta (volatility vs the S&P 500)0.72

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $63, high $87, latest $75. $87 $63 high $87 Oct 17, 2025 Nov 19, 2026 · $75 $75Oct 17, 2025$74Oct 31, 2025$78Nov 14, 2025$79Nov 28, 2025$79Dec 12, 2025$80Dec 26, 2025$80Jan 9, 2026$80Jan 23, 2026$79Feb 6, 2026$83Feb 20, 2026$81Mar 6, 2026$74Mar 20, 2026$75Apr 2, 2026$81Apr 17, 2026$74May 1, 2026$64May 15, 2026$66May 29, 2026$67Jun 12, 2026$68Jun 26, 2026$68Jul 10, 2026$68Jul 24, 2026$72Aug 7, 2026$74Aug 21, 2026$71Sep 4, 2026$65Sep 18, 2026$64Oct 2, 2026$66Oct 16, 2026$71Oct 30, 2026$74Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Alcon (ALC): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Moderate
Growth Durability Moderate
Momentum Moderate

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 14, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Moderate
ROE Weak
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Alcon (ALC), and what does it report?

Short answer · as of

Alcon is an eye-care manufacturer with Surgical and Vision Care operations, not simply a medical-equipment vendor. A cataract procedure can involve its diagnostics, visualization systems or surgical platform, followed by demand for implantable lenses, solutions, instruments and custom packs; Vision Care adds replenishment demand from contact lenses and ocular-health products.

Consolidated revenue therefore blends equipment purchases, procedure-linked products and repeat consumer use. That mix matters because hospital capital budgets, surgical activity and contact-lens demand can move differently, while research spending supports products across the portfolio.

2 · Latest results

What do the latest results show for Alcon (ALC)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $2.82B.

The latest income statement shows revenue and gross profit rising from the preceding period, but research and development expense surged, selling and administrative expense also increased, and reported operating profit nearly disappeared. The earnings record simultaneously shows sales and per-share earnings above expectations, so the headline beat did not translate into comparable reported operating conversion.

Management expects harder equipment comparisons to be partly offset by more favorable contact-lens comparisons. It also expects TRYPTYR, Valeda, UNITY CS and PanOptix Pro in Europe to contribute more as the year progresses, while planned reinvestment of a government refund and a broadly stable selling-and-administrative burden relative to sales could limit near-term profit flow-through.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$2.82B$0$0.00 (diluted)
Q1 FY2026$2.65B$185M$0.38 (diluted)
Q4 FY2025$2.72B$217M$0.44 (diluted)
Q3 FY2025$2.61B$237M$0.48 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Alcon (ALC)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow remained positive and exceeded capital spending throughout the reported window, giving Alcon internally generated funding despite uneven accounting profit. Annual revenue has advanced across successive reported periods, although the latest annual net result eased as research spending rose.

Debt substantially exceeds cash and short-term investments, even after long-term investments are included. Cash and short-term investments declined across the reported window, while the latest liquidity ratios indicate that short-term assets still cover short-term obligations; the strong quality screen does not remove the burden created by net debt and weak recent reported margins.

The business is most exposed when equipment demand slows while launch, research and commercial spending remain elevated. A rising annual dividend adds another recurring cash claim, so continued cash generation after capital spending matters more than the cash balance alone.

4 · What to check next?

What should you watch next at Alcon (ALC)?

Short answer · as of

Current published price targets run low $35.00 · high $98.00 · consensus $78.39 · median $84.50 against a quoted price of $74.52 (as of Nov 19, 2026).

Watch whether UNITY CS, TRYPTYR, Valeda and PanOptix Pro produce visible sales contributions while contact-lens comparisons improve. Those gains need to offset harder equipment comparisons without requiring selling and administrative spending to consume the benefit.

Reported operating conversion deserves particular attention after gross profit rose but operating profit nearly vanished. The scheduled earnings release can also test whether sales and per-share earnings continue to clear expectations and whether consensus assumptions for longer-run expansion remain plausible.

Cash flow offers the cleanest cross-check: operating cash should continue to cover capital spending, while cash and short-term investments should stabilize rather than extending their decline.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Alcon compare with its peers?

Short answer

Alcon's score ranks 4th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Alcon combines capital equipment, procedure-specific consumables and implantable lenses with a separate contact-lens and ocular-health franchise. A pure equipment maker depends more directly on purchasing cycles, while a pure contact-lens business lacks Alcon’s exposure to surgical procedures and the associated demand for lenses, packs, solutions and instruments.

That breadth creates distinct demand rhythms inside the same company: equipment purchases can be intermittent, procedure products move with surgical activity, and Vision Care products depend more on replenishment. The mix can cushion weakness in a product category, but it can also leave strong sales growth paired with poor operating conversion when development and commercial spending rise.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ResMed Inc. (RMD) Named competitor$242.61 Nov 18, 2026$34.1B95 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
Agilent Technologies, Inc. (A) Named competitor$177.33 Nov 18, 2026$50.0B83 5-pillar Nov 18, 2026
Alcon (ALC) — this page$74.52$35.8B80
IQVIA Holdings Inc. (IQV) Named competitor$257.84 Nov 18, 2026$42.5B71 5-pillar Nov 18, 2026
Becton, Dickinson and Company (BDX) Named competitor$212.73 Nov 19, 2026$57.9B68 5-pillar Nov 18, 2026
Inspira Technologies Oxy B.H.N. Ltd. (QTEX) Same industry, near in market value$1.12 Nov 18, 2026$75.1M45 5-pillar Nov 18, 2026
SHOULDER INNOVATIONS, INC. (SI) Same industry, near in market value$20.65 Nov 18, 2026$432M34 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$35.00 – $98.00
Consensus target
$78.39
Median target
$84.50

Consensus record · Captured .

Measured against a quoted price of $74.52 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ALC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About ALC (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

How do UNITY CS and PanOptix Pro fit into Alcon’s growth plan?

UNITY CS expands Alcon’s cataract-surgery equipment offering, while PanOptix Pro adds to its implantable-lens portfolio. Management expects their launch contributions to become more meaningful as the year progresses.

Why do equipment and contact-lens comparisons pull Alcon in different directions?

Equipment demand reflects purchasing cycles for surgical systems, whereas contact lenses depend on repeat use and replenishment. Management expects harder equipment comparisons alongside more favorable contact-lens comparisons.

Why did Alcon’s reported operating profit weaken while gross profit rose?

Research and development expense increased sharply and selling and administrative expense also rose, absorbing the higher gross profit. The result was a steep deterioration in reported operating conversion despite higher revenue.

Does Alcon’s surgical model generate cash after capital spending?

Operating cash flow exceeded capital spending throughout the reported window. That cash generation is important because debt remains above cash and investments, while cash and short-term investments have declined.

What is the ALC stock price today?

The last price recorded for Alcon Inc. (ALC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ALC price target?

The analyst consensus price target for Alcon Inc. (ALC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Ticker / exchange; Business description; Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 1. What is Alcon (ALC), and what does it report?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Alcon (ALC)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Annual revenue and net result (USD millions)
  • 3. What are the financial strengths and risks for Alcon (ALC)?: Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Trailing twelve-month ratio set; Distress and quality screens; Recent dividends paid
  • 4. What should you watch next at Alcon (ALC)?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Next earnings report; Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does Alcon compare with its peers?: Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • FAQ: How do UNITY CS and PanOptix Pro fit into Alcon’s growth plan?: Business description; Management outlook — dated call excerpts
  • FAQ: Why do equipment and contact-lens comparisons pull Alcon in different directions?: Business description; Management outlook — dated call excerpts
  • FAQ: Why did Alcon’s reported operating profit weaken while gross profit rose?: Quarterly income statement (USD thousands)
  • FAQ: Does Alcon’s surgical model generate cash after capital spending?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.